A Smooth Handoff From Decision to Dollars: Connecting the Last Mile in Healthcare Payments
Healthcare payments face a hidden bottleneck between payer adjudication and provider cash receipt, causing revenue leakage and cash‑flow volatility. Even with optimized front‑end processes, mismatched remittance data, paper checks, and manual reconciliations stall payments for days. This friction not only inflates labor costs but also creates confusing billing experiences that erode patient trust. Addressing the last‑mile handoff with purpose‑driven automation can streamline cash flow and improve the overall financial journey.
Full 4th Circuit to Rehear Challenges to State Contract Pharmacy Laws
The full 4th U.S. Circuit Court of Appeals agreed on May 28 to rehear challenges to 340B contract‑pharmacy laws in West Virginia and Maryland. A three‑judge panel had earlier ruled those state statutes unconstitutional, a decision the American Hospital Association (AHA) criticized...
CMS Finalizes Changes to Increasing Organ Transplant Access Model
On May 28, CMS issued a final rule updating the six‑year Increasing Organ Transplant Access (IOTA) Model, effective July 1. The low‑volume threshold for kidney‑transplant hospitals was raised from 11 to 15 transplants per year, and Medicare Advantage beneficiaries will now be...
Naloxone Use During Cardiac Arrest Linked to Improved Survival
Researchers at UC Davis Health analyzed 3,811 out‑of‑hospital cardiac arrests in California and found that administering naloxone during EMS resuscitation was linked to higher survival rates. Patients who received naloxone survived to hospital discharge at 8.1% versus 4.4% for those...
Controversial Oncology Drug Gets Third Review From FDA
Replimune has resubmitted its oncology therapy RP1 for a third FDA review, hoping new agency leadership will overturn the earlier rejection. The drug, which targets a novel tumor antigen, was previously declined under former commissioner Marty Makary and deputy Vinay...
Arkansas Hospital CEO to Step Down After 11 Years for New Role
Matt Troup will leave his role as president and CEO of Conway Regional Health System after more than eleven years, taking an out‑of‑state market president position on July 17. During his tenure, the Arkansas‑based system expanded specialty services, added outpatient...
Dexcom Warns Stolen G7 Glucose Sensors May Pose Infection, Reading Risks
Dexcom disclosed that two lots of its G7 continuous glucose monitor sensors were stolen during the disposal process and later sold through an unauthorized Georgia wholesaler. The affected lots—1725204004 and 1725069002—pose distinct health risks: potential skin infections and possible loss...
Antibacterial Susceptibility Test Interpretive Criteria
The FDA has published a comprehensive table showing which antibacterial drugs have recognized susceptibility test interpretive criteria (STIC) based on CLSI standards. For most agents, the agency fully endorses the breakpoints in CLSI’s 2026 M100 supplement, while noting specific exceptions...
CareFor Unveils New Hospice Program
Texas‑based care management firm CareFor has introduced CareFor Hospice, its first dedicated hospice service in the Austin region. The program provides comprehensive symptom management, emotional support, caregiver education and 24/7 clinical coverage, with nursing visits at least twice a week...
Grady Health System Goes Live with Sectra Amplifier Services to Enable Smooth Implementation of AI—Enhancing Diagnostic Workflows Across Sites
Grady Health System, one of the largest U.S. safety‑net providers, has gone live with Sectra Amplifier Services, a cloud‑based AI‑as‑a‑Service platform that streamlines deployment of diagnostic algorithms. The rollout includes Avicenna.ai’s CINA Chest and Therapixel’s Mammoscreen, enabling faster, more accurate...
Why Pre-Admission Is Hospice’s Next Operational Advantage
Redwood Hospice in San Jose adopted ArcHouse’s pre‑admission platform to automate referral management and speed patient intake. The system consolidates clinical documents, tracks referral status in real time, and enables a physician‑run clinical review before a nurse visit. As a...
How Prisma Health Turned Data Into a Frontline Care Strategy
Prisma Health leveraged Innovaccer’s population‑health platform to stitch together clinical, claims, pharmacy and real‑time ADT data into a unified longitudinal patient record. The system generates a composite risk score across clinical, financial, adherence and social‑determinant domains, automatically routing patients to...
Regulatory Actions for May 29, 2026
On May 29, 2026 regulators released a flurry of decisions affecting biopharma and med‑tech firms, spanning approvals, designations and new submission filings. Companies such as AbbVie, Sanofi, Cogent, Ironwood, Enterome and Gene Solutions were among those highlighted. The actions include FDA approvals...
SAPT After TAVR Linked to Key Benefits over DAPT, New Data Confirm
New registry data from the TRITAVI cohort show that single antiplatelet therapy (SAPT) after transcatheter aortic valve replacement (TAVR) markedly improves survival compared with dual antiplatelet therapy (DAPT). Among more than 5,000 patients with a mean age of 81, six‑month...
ASCO: BMS Hails "Compelling" Phase 3 Celmod Readout
Bristol Myers Squibb presented phase 3 data for mezigdomide, a cereblon E3 ligase modulator, combined with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma. The SUCCESSOR‑2 trial showed a 52% reduction in progression or death risk and a median progression‑free survival of...
Bridging the Diagnostics Gap: Deloitte Research Exposes Core Mismatch Between Manufacturers and Providers
Deloitte’s latest survey of 50 diagnostics manufacturers and 50 providers shows a stark strategic mismatch. While 62% of manufacturers view a B2B2C model as essential for growth, providers rank test ordering as their biggest workflow friction and demand seamless consumer‑initiated...
Uninsurance Rate Holds Flat in 2025: CDC
The CDC’s preliminary 2025 report shows the uninsurance rate holding steady at 8.3%, or roughly 28 million Americans, matching 2024 levels. Adults ages 18‑64 remain the most exposed group at 11.6% without coverage, while children and seniors sit at 5.6% and...
J&J Recalls Impella Heart Pumps After Patient Dies
Johnson & Johnson’s Abiomed unit recalled seven Impella CP Sets with SmartAssist after an internal review linked the devices to low purge pressure events that caused one patient death and three pump exchanges. The defect appeared in just 0.01 % of over...
Shifting the Interoperability Axis: Why Layered Extensions Fail Modern Hospital Core EHRs
Hospital admissions total 33.5 million annually, with healthcare spending at $4.9 trillion. A 2026 CHIME survey shows 90% of CIOs prioritize vendor consolidation, yet only 16% have interoperability built into the EHR core. Cost, vendor resistance and data silos drive 47% of...
Retatrutide Results Spark Questions About How Rapid Weight Loss Affects the Body
Retatrutide, Eli Lilly's next‑generation GLP‑1 agonist, produced a 28.3% average body‑weight loss (about 70 lb) over 80 weeks, rivaling bariatric surgery. The drug’s triple‑receptor action outperforms existing agents like Wegovy and Zepbound, prompting expectations of imminent FDA approval. However, rapid weight...
Which Virtual Assistant Delivers for Medical Offices? Key Features and Leaders
Medical offices are turning to virtual assistant services to offset staffing shortages and streamline administrative tasks such as scheduling, billing, and patient communication. Providers like My Mountain Mover, Hello Rache, CareXM, Phoenix Virtual Solutions, and MedVA each emphasize HIPAA‑trained staff...
STAT+: Pharmalittle: We’re Reading About Replimune Drug Getting Third Try at FDA Approval, a Pfizer Deal in China, and More
An FDA advisory panel recommended that this fall’s COVID‑19 vaccines be updated to target the fast‑growing XFG (“stratus”) variant. Pfizer signed a global licensing and collaboration deal with China’s Innovent Biologics worth up to $10.5 billion to co‑develop 12 early‑stage cancer...
Replimune Gives Cancer Immunotherapy a Third Try After FDA Leadership Shakeup
Replimune is filing a third biologics license application for its oncolytic melanoma therapy RP1, now paired with Bristol Myers Squibb’s PD‑1 inhibitor Opdivo. The FDA has labeled the resubmission an urgent matter and will prioritize its review. Earlier submissions were rejected...
The EHR Was Built to Store Data — It Wasn’t Built to Orchestrate Care
Electronic health records were designed as comprehensive data repositories, not as tools to direct patient care. Clinicians now face an average of 359 notes per patient, creating information overload that hampers decision‑making. The article argues for a dedicated orchestration layer—often...
On June 5 #HAVHope Friday and All Days, Hospitals Are Leading the Way to Safer Communities
The American Hospital Association marks the 10‑year anniversary of #HAVhope Friday on June 5, 2026, spotlighting hospitals’ expanding role in violence prevention. Through the Hospitals Against Violence initiative, health systems are deploying community‑based intervention programs, expanding behavioral health services, and partnering...
The Illusion of Visibility: Why More Data Doesn’t Mean Better Decisions
Healthcare executives are overwhelmed by a flood of dashboards that track patient flow, costs, utilization and revenue cycle metrics, yet the sheer volume creates noise rather than clarity. The article argues that more data does not automatically translate into better...
Garner Health Secures $100M at $2.74B Valuation to Scale Clinical Quality Infrastructure
Garner Health closed a $100 million Series E round, valuing the company at $2.74 billion. The funding will expand its AI‑driven platform that analyzes 60 billion medical records to generate quality scores for providers. Garner’s infrastructure already supports $200 million in annual recurring revenue, doubling...
Pharmacy First Prescribing Expanded to Ease GP Pressure
The UK government has unveiled a £340 million (≈ $430 million) programme to broaden the range of medicines community pharmacists in England can prescribe, adding five new therapeutic categories to the existing Pharmacy First list. The move, part of the 2024‑2025 Pharmacy First...
Ambience Healthcare Launches Chart-Aware Inpatient AI Suite to Resolve 91% of Documentation Gaps
Ambience Healthcare has expanded its chart‑aware AI across the inpatient workflow, embedding deep EHR reasoning into progress notes, H&P notes, and discharge summaries. Internal data show that 70% of clinically important inpatient diagnoses are invisible to audio‑only transcription, prompting the...
Longevity Science Picks up Steam in Pharma
Longevity science is moving from fringe research into mainstream drug development, with Life Biosciences' ER‑100 becoming the first epigenetic reprogramming therapy to enter human trials. Retro Biosciences and Lysoway Therapeutics have also advanced neurodegeneration candidates into Phase 1, targeting autophagy pathways....
Targeted Therapy Shows Superior Results Over Chemotherapy in Treating Difficult Lung Cancer, ASCO Reports
At the American Society of Clinical Oncology (ASCO) meeting, researchers presented data showing a novel targeted therapy outperformed standard chemotherapy in patients with advanced non‑small cell lung cancer (NSCLC) that are difficult to treat. The trial reported a median progression‑free...
Merck Secures the US FDA Breakthrough Therapy Designation for Calderasib to Treat Newly Diagnosed Metastatic KRAS G12C-Mutant NSCLC
The U.S. FDA granted Merck’s KRAS‑G12C inhibitor calderasib (MK‑1084) breakthrough therapy designation for first‑line treatment of newly diagnosed metastatic non‑small cell lung cancer (NSCLC) that harbors a KRAS G12C mutation and expresses PD‑L1 (TPS ≥ 1%). The designation is backed by Phase I...
Medtronic: Strengthening Regulated Medical Device Supply Chains
Medtronic, one of the world’s largest medical‑technology firms, is redefining its supply‑chain model to meet the stringent demands of regulated healthcare. Beyond cost and service, the company now measures performance on traceability, documentation integrity, and compliance continuity, requiring end‑to‑end visibility...
Technology
The article highlights the mechanical thrombectomy device, commonly known as a stent retriever, which received FDA approval in 2004 and has transformed treatment for ischemic strokes. By threading a catheter into blocked brain arteries, the device physically extracts clots, restoring...
Altimmune Reports the P-IIb (IMPACT) Trial Data on Pemvidutide for Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Altimmune presented 48‑week Phase‑IIb (IMPACT) results for its GLP‑1‑GIP agonist pemvidutide in 212 patients with metabolic dysfunction‑associated steatohepatitis (MASH) and fibrosis stage F2‑F3. The 1.8 mg weekly dose cut triglycerides by 23.7%, total cholesterol by 15.4%, lowered BMI by 3 kg/m², reduced...
UnitedHealthcare Reduces Most Prior Approvals For Pediatric Patients
UnitedHealthcare announced it will eliminate roughly two‑thirds of prior‑authorization requirements for members under 18 by year‑end. The change covers many diagnostic, routine surgical and specialty‑care services across its commercial and Medicaid pediatric plans. The insurer will also issue waivers for...
GSK’s Nucala Secures NICE COPD Endorsement
NICE has added GSK’s Nucala (mepolizumab) to its list of approved biologic add‑on treatments for chronic obstructive pulmonary disease (COPD) in patients with elevated eosinophils. The endorsement is based on three Phase III trials that demonstrated up to a 21 % reduction...
Clinical Ambitions and Retail Realities: Analysis of Best Buy's Acquisition and Divestiture of Current Health
Best Buy acquired remote‑patient‑monitoring firm Current Health in late 2021 for roughly $400 million, aiming to blend its Geek Squad logistics with clinical wearables under the Best Buy Health banner. By mid‑2025 the retailer reversed course, selling Current Health back to founder Christopher McGhee, laying off staff and...
Tariffs and Geopolitics Are Reshaping Pharma Supply Chains
AlixPartners' 2026 U.S. Healthcare & Life Sciences Survey finds tariffs, geopolitical tensions and rising costs are top supply‑chain challenges for pharma and medical‑device firms. Nearly 30% of respondents cite disruptions as their primary pain point, while 26% point to tariff...
Radiopharma on the Rise: Are Supply Chains Ready?
Radiopharmaceutical therapies are moving from niche innovation to mainstream oncology, driven by a surge in approvals and a rapidly expanding clinical pipeline. GlobalData projects sales of radioligand therapies to exceed $2 billion in 2024 and climb above $10.5 billion by 2031, reflecting...
Ultrasound Analytics Take Digital Transformation a Step Forward
The Centre Hospitalier de Luxembourg (CHL) has deployed GE HealthCare’s Ultrasound Excellence platform to turn routine ultrasound metadata into actionable operational dashboards. Daily‑ refreshed data and weekly reports now give clinical, biomedical and operations teams a consolidated view of exam...
Pancreatic Cancer Halted by Virus Injection in Three Patients
In a U.S. Phase 1 safety trial, an engineered oncolytic virus halted tumor growth and prevented spread in three pancreatic cancer patients. Researchers administered only one‑tenth of the intended therapeutic dose, yet observed clear disease control. Lead developer Masato Yamamoto highlighted...
California Senate Passes Bill that Would Create $12B in State Research Funding
California’s Senate approved SB 895, a bill that would issue $12 billion in bonds to launch the California Foundation for Science and Health Research. The foundation would award grants to public and private institutions, prioritizing projects displaced by federal cuts under the...
Kalohexis Doses First Patients in 710GO Phase I Trial for Obesity
Kalohexis has begun dosing the first participants in a Phase I, first‑in‑human trial of 710GO, an oral dual melanocortin‑3/4 receptor agonist aimed at treating general obesity. The randomized, double‑blind, placebo‑controlled study in Australia will enroll roughly 100 obese or overweight volunteers...
AMA: Healthcare GenMat: Generative Design for Patient-Specific Orthopedic Implants
GenMat’s Ossevo platform introduces a bio‑inspired design workflow that mimics bone’s natural remodeling to create patient‑specific orthopedic implants. By using a hybrid cellular automata algorithm, the system generates graded lattice structures whose geometry varies with local mechanical stimulus, aiming to...
Samsung Bioepis Reports the EC Launch of Opuviz (Biosimilar, Eylea)
Samsung Bioepis announced the European commercial launch of Opuviz 40 mg/mL solution for injection, a biosimilar to aflibercept (Eylea). The product will be sold directly by the company across the EU for wet age‑related macular degeneration, diabetic macular oedema, retinal vein...
HIV Disclosure and Prevention Advocacy Partially Mediate Advocacy Training Intervention Effect on Reduced Internalized HIV Stigma
A randomized controlled trial in Uganda tested the Game Changers for HIV Prevention peer‑advocacy training on 210 people living with HIV. Over 18 months the intervention lowered internalized HIV stigma compared with usual care. Mediation analysis showed that increased HIV...
Australia Sets Out National Framework for Digital Health Standards
The Australian Digital Health Agency released a National Framework for Digital Health Standards to unify interoperability, governance and AI‑ready terminology across the health sector. The framework builds on the 2023‑2028 Digital Health Strategy, mandates HL7 FHIR adoption, and introduces a...
Where Medical Expertise Meets Advanced Skin Care: Manila Doctors Hospital Now Offers Skin and Laser Services
Manila Doctors Hospital (MDH) has opened a hospital‑based Skin and Laser Center within its Aesthetics Center, delivering medical‑grade dermatology and laser procedures under clinical supervision. Led by chief dermatologist Dr. Cindy Jao Tan and a team of board‑certified specialists, the...
Procept Secures FDA IDE for Aquablation and Completes WATER IV Study Enrolment
Procept BioRobotics secured a second FDA investigational device exemption (IDE) to launch a new randomized trial of its Aquablation water‑jet therapy, this time comparing it with active surveillance in men with low‑grade prostate cancer. The earlier WATER IV study has already...